On June 5, 2023, immediately following the closing of the Private Placement, the Board of Directors of Telesis Bio, Inc. was increased from seven to eight directors and Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3184 USD | -0.93% | +3.04% | -20.20% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.20% | 9.58M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio, Inc. Appoints Paul Meister as Director